248 related articles for article (PubMed ID: 24324705)
1. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
2. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
3. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
4. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
5. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCĪ³1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
6. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
[TBL] [Abstract][Full Text] [Related]
7. Statins do not inhibit the FGFR signaling in chondrocytes.
Fafilek B; Hampl M; Ricankova N; Vesela I; Balek L; Kunova Bosakova M; Gudernova I; Varecha M; Buchtova M; Krejci P
Osteoarthritis Cartilage; 2017 Sep; 25(9):1522-1530. PubMed ID: 28583899
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
[TBL] [Abstract][Full Text] [Related]
9. ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.
Balek L; Gudernova I; Vesela I; Hampl M; Oralova V; Kunova Bosakova M; Varecha M; Nemec P; Hall T; Abbadessa G; Hatch N; Buchtova M; Krejci P
Bone; 2017 Dec; 105():57-66. PubMed ID: 28826843
[TBL] [Abstract][Full Text] [Related]
10. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation.
Yamanaka Y; Tanaka H; Koike M; Nishimura R; Seino Y
J Bone Miner Res; 2003 Aug; 18(8):1395-403. PubMed ID: 12929929
[TBL] [Abstract][Full Text] [Related]
11. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.
Krejci P; Salazar L; Kashiwada TA; Chlebova K; Salasova A; Thompson LM; Bryja V; Kozubik A; Wilcox WR
PLoS One; 2008; 3(12):e3961. PubMed ID: 19088846
[TBL] [Abstract][Full Text] [Related]
12. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
13. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.
Krejci P; Masri B; Fontaine V; Mekikian PB; Weis M; Prats H; Wilcox WR
J Cell Sci; 2005 Nov; 118(Pt 21):5089-100. PubMed ID: 16234329
[TBL] [Abstract][Full Text] [Related]
14. Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.
Funahashi H; Matsushita M; Esaki R; Mishima K; Ohkawara B; Kamiya Y; Takegami Y; Ohno K; Kitoh H; Imagama S
JBMR Plus; 2024 Apr; 8(4):ziae018. PubMed ID: 38544920
[TBL] [Abstract][Full Text] [Related]
15. Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells.
Ozasa A; Komatsu Y; Yasoda A; Miura M; Sakuma Y; Nakatsuru Y; Arai H; Itoh N; Nakao K
Bone; 2005 Jun; 36(6):1056-64. PubMed ID: 15869918
[TBL] [Abstract][Full Text] [Related]
16. Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish.
Takemoto G; Matsushita M; Okamoto T; Ito T; Matsuura Y; Takashima C; Chen-Yoshikawa TF; Ebi H; Imagama S; Kitoh H; Ohno K; Hosono Y
Front Cell Dev Biol; 2021; 9():694018. PubMed ID: 35118060
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
[TBL] [Abstract][Full Text] [Related]
18. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for the treatment of achondroplasia.
Yamanaka Y; Ueda K; Seino Y; Tanaka H
Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
[TBL] [Abstract][Full Text] [Related]
20. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
